Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of Bristol-Myers Squibb Co. (NYSE: BMY) were yielding above the 3% mark based on its quarterly dividend (annualized to $1.40), with the stock changing hands as ...

Bristol-Myers Squibb Co. (NYSE: BMY): By the end of last trading session, the shares of Bristol Myers Squibb (NYSE: BMY) soared US$2.34 (or 5.31%) to US$46.40 with 25.35 million shares exchanged hands, compared to daily average volume of 10.39 ...

Capstone Turbine Corporation (NASDAQ:CPST) shares jumped 5.08% to $0.904. The company, on April 8, announced that it received an order for thirty-four liquid fuel C30s for use in DesignLine'sEco Saver IV range extended electric buses.

Sprycel: Developed by Bristol Myers Squibb Co. (NYSE:BMY), Sprycel was approved in 2006 as a second-line treatment for patients who had Philadelphia chromosome-positive (Ph+) ALL or Ph+ CML, and had resistance to prior therapy.

Saed Hindash/The Star-Ledger. Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.

Bristol-Myers Squibb Company (NYSE: BMY) will present at the UBS Global Health Care Conference on Tuesday, May 21, 2013, in New York City.

Merus Labs International Inc. (NASDAQ: MSLI) (TSX: MSL) is a specialty pharmaceutical company focused on the licensing and acquisition of recognized products that are under-promoted from larger pharmaceuticals.

Bristol-Myers Squibb Company (NYSE: BMY) will present at Bank of America Merrill Lynch Health Care Conference on Wednesday, May 15, 2013, in Las Vegas.

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bristol-Myers Squibb Company (NYSE:BMY), Sanofi (NYSE:SNY), AbbVie (NYSE:ABBV) ...

... and have been preparing for the presentation of key clinical data across our pipeline." Bristol-Myers Squibb Co. sees FY2013 EPS of $1.78-1.88, versus the consensus of $1.83. For earnings history and earnings-related data on Bristol-Myers Squibb Co.